Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019.

ABSTRACT:

Background

Remdesivir is efficacious for severe coronavirus disease 2019 (COVID-19) in adults, but data in pregnant women are limited. We describe outcomes in the first 86 pregnant women with severe COVID-19 who were treated with remdesivir.

Methods

The reported data span 21 March to 16 June 2020 for hospitalized pregnant women with polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 infection and room air oxygen saturation ≤94% whose clinicians requested remdesivir through the compassionate use program. The intended remdesivir treatment course was 10 days (200 mg on day 1, followed by 100 mg for days 2-10, given intravenously).

Results

Nineteen of 86 women delivered before their first dose and were reclassified as immediate "postpartum

SUBMITTER: Burwick RM 

PROVIDER: S-EPMC7797739 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature